Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000342939

Medchemexpress LLC PT-2385 | 1672665-49-4 | 100.0% | 100 MG
SDP

Catalog No. 5000342939
Encompass_Preferred

PT-2385 is a highly selective HIF-2α inhibitor, demonstrating a Ki of less than 50 nM. It acts as an antagonist specifically targeting HIF-2 over HIF-1, with no activity against HIF-1α. In preclinical studies, PT-2385 has shown significant in vivo activity by inhibiting the expression of HIF-2α regulated genes in a dose-dependent manner. This compound has also been observed to induce rapid, dose-dependent tumor regression in models using 786-O and A498 RCC cell lines, typically when administered at 30 or 100 mg/kg via oral gavage twice daily. Additionally, it contributes to reducing tumor-derived VEGFA protein levels, which in turn diminishes proliferation (Ki67) and angiogenesis (CD-31).

  • Selective HIF-2α inhibitor
  • Inactive against HIF-1α
  • Inhibits HIF-2α regulated gene expression
  • Induces tumor regression in preclinical models
  • Reduces tumor proliferation and angiogenesis

Catalog No. 50-003-42939 Supplier Medchemexpress LLC Supplier No. HY12867100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

PT-2385 is a highly selective HIF-2α inhibitor, demonstrating a Ki of less than 50 nM. It acts as an antagonist specifically targeting HIF-2 over HIF-1, with no activity against HIF-1α. In preclinical studies, PT-2385 has shown significant in vivo activity by inhibiting the expression of HIF-2α regulated genes in a dose-dependent manner. This compound has also been observed to induce rapid, dose-dependent tumor regression in models using 786-O and A498 RCC cell lines, typically when administered at 30 or 100 mg/kg via oral gavage twice daily. Additionally, it contributes to reducing tumor-derived VEGFA protein levels, which in turn diminishes proliferation (Ki67) and angiogenesis (CD-31).

  • Selective HIF-2α inhibitor
  • Inactive against HIF-1α
  • Inhibits HIF-2α regulated gene expression
  • Induces tumor regression in preclinical models
  • Reduces tumor proliferation and angiogenesis

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.